A clinical trial fell short of producing statistical evidence that Novartis’ anti-inflammatory drug Cosentyx can beat the world’s best-selling medicine Humira in treating a type of arthritis.
Breast Cancer: Steady Progress Being Made in New Treatments
Antigens, Breast Cancer, Cancer Cells, Checkpoint Inhibitors, Clinical Data, Clinical Trials, Genetics, HER2-positive breast cancer, Postmenopausal, R&D, T-Cells, U.S. Centers for Disease Control and Prevention, Washington University School of Medicine in St. LouisFor Breast Cancer Awareness Month, BioSpace gathered examples of recent breakthroughs in breast cancer treatment.
U.S. regulators halted a trial of Novartis’ Zolgensma treatment after an animal study raised safety concerns, in a setback for the drugmaker’s plan to expand the product’s use to older patients.
AstraZeneca Plc’s cancer drug Imfinzi in combination with chemotherapy and the company’s cancer medicine tremelimumab met the main goal of delaying progression of a form of lung cancer.
GlaxoSmithKline Plc started a late-stage study testing the company’s experimental antibiotic gepotidacin in patients with urinary tract infections and gonorrhoea.
MacroGenics’ metastatic HER2-positive breast cancer drug margetuximab continued to show promise in a second pre-planned interim overall survival analysis of the Phase III SOPHIA trial.
J&J’s Janssen Pharmaceutical released new long-term data from the open-label period of the Phase III VOYAGE 1 study.
A little more than a week after announcing plans to acquire Ra Pharmaceutical for $2.1 billion, UCB’s psoriasis drug bimekizumab met all endpoints in the first of three Phase III studies.
Eli Lilly and Co.’s experimental pancreatic cancer treatment in combination with chemotherapy drugs failed to meet the main goal of overall survival in a late-stage study.
Reata Pharmaceuticals Inc.’s Part 2 portion of the MOXIe Phase 2 trial of omaveloxolone in patients with Friedreich’s ataxia (FA) met the primary endpoint of change in the modified Friedreich’s Ataxia Rating Scale relative to placebo after 48 weeks of treatment.
